D-enantiomeric peptides derived from D3 and use thereof
The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.
1. A peptide containing at least one amino acid sequence, wherein the peptide comprises at least 50% D-enantiomeric amino acids and the at least one amino acid sequence is SEQ ID NO: 5 or a homolog thereof with a sequence identity of at least 83%.
2. The peptide of claim 1 , wherein the peptide is substantially composed of D-amino acids.
3. The peptide of claim 1 , wherein the peptide is capable of inhibiting formation of fibrils of amyloid beta peptides.
4. The peptide of claim 1 , wherein the peptide is capable of binding to aggregated amyloid beta peptides.
5. The peptide of claim 1 , wherein the peptide is capable of being used as a therapeutic agent in medicine.
6. The peptide of claim 1 , wherein the peptide is capable of treating Alzheimer's disease.
7. A pharmaceutical composition, wherein the composition comprises as one of the components thereof the peptide of claim 1 .
8. A probe for the identification and quantitative and/or qualitative determination of amyloid beta fibrils and/or amyloid beta oligomers, wherein the probe comprises the peptide of claim 1 .
9. A kit, wherein the kit comprises the peptide of claim 1 .
10. The peptide of claim 1 , wherein the peptide is linked to a further substance.
11. The peptide of claim 1 , wherein the at least one amino acid sequence is SEQ ID NO: 5.
12. A pharmaceutical composition, wherein the composition comprises as one of the components thereof the peptide of claim 11 .
13. A probe for the identification and quantitative and/or qualitative determination of amyloid beta fibrils and/or amyloid beta oligomers, wherein the probe comprises the peptide of claim 11 .
14. A kit, wherein the kit comprises the peptide of claim 11 .
15. A method for the detoxification of toxic amyloid beta oligomers and/or aggregates, wherein the method comprises contacting the oligomers and/or aggregates with the peptide of claim 11 .
16. A method for preparing the peptide of claim 1 , wherein the method involves peptide synthesis or mutagenesis.
17. A method for the detoxification of toxic amyloid beta oligomers and/or aggregates, wherein the method comprises contacting the oligomers and/or aggregates with the peptide of claim 1 .
18. The method of claim 17 , wherein the amyloid beta oligomers and/or aggregates form amorphous, non-toxic aggregates with the peptide.